Celldetect test performance in monitoring bladder cancer recurrence after transurethral resection.
CellDetect test showed high negative predictive value for excluding bladder cancer recurrence
Celldetect test performance in monitoring bladder cancer recurrence after transurethral resection.
Non-muscle-invasive bladder cancer (non-muscle-invasive bladder cancer) has a high recurrence rate, necessitating rigorous surveillance primarily reliant on invasive cystoscopy.
This study aimed to evaluate its real-world diagnostic performance for detecting non-muscle-invasive bladder cancer recurrence.
This retrospective cohort study included 243 patients under surveillance after transurethral resection of bladder tumor (transurethral resection of bladder tumor).
a negative test result reliably rules out bladder cancer recurrence
Sensitivity was significantly higher for high-grade (high-grade) tumors (93.8%) than for low-grade (low-grade) tumors (69.4%).
In the high-risk European Organization for Research and Treatment of Cancer subgroup, sensitivity was 88.9% and negative predictive value was 95.2%.
Furthermore, among 18 patients with “discordant” findings (positive CellDetect/ negative cystoscopy), 6 (33.3%) were subsequently diagnosed with recurrence upon random biopsy.
In this retrospective analysis, the CellDetect test demonstrated encouraging diagnostic performance in the post-transurethral resection of bladder tumor surveillance setting, particularly its high negative predictive value and sensitivity for high-grade tumors.
“Discordant” results may hold predictive value for imminent recurrence. Further prospective validation is warranted.
CellDetect represents a potential tool for developing a more personalized, risk-adapted, and patient-friendly follow-up strategy for non-muscle-invasive bladder cancer.